2023
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
Shaked Y, Benguigui M, Halaban R, Bacchiocchi A, Kamer I, Bar J, Lotem M, Shen-Orr S, Sznol M, Cooper T. A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. Journal Of Clinical Oncology 2023, 41: 2557-2557. DOI: 10.1200/jco.2023.41.16_suppl.2557.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsCell lung cancerImmunotherapy outcomesImmunotherapy responseMelanoma patientsCancer patientsLung cancerT cellsImmune checkpoint inhibitor-based therapyNew biomarkersNon-small cell lung cancerAdvanced metastatic NSCLCAnti-PD1 responseImmunotherapy-treated patientsMyeloid cell compositionPDL-1 expressionSubset of neutrophilsAnti-PD1 therapyMalignant melanoma patientsBlood mononuclear cellsInhibitor-based therapyPre-clinical modelsRenal cell carcinomaBlood-borne biomarkersSuccessful clinical trials
2008
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents
Lilenbaum R, Herbst R. Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 2008, 15: 352-358. DOI: 10.1097/cpm.0b013e31818cd61f.Peer-Reviewed Original ResearchCell lung cancerMetastatic NSCLCOverall survivalLung cancerPatient outcomesAdvanced metastatic NSCLCThird-line settingBest supportive careProgression-free survivalAntiangiogenic agent bevacizumabOverall patient survivalPatient selection criteriaOngoing clinical trialsEpidermal growth factor receptorGrowth factor receptorRefractory settingAgent bevacizumabSupportive careTargeted agentsOptimal therapyChemotherapeutic regimensPatient survivalClinical trialsResponse rateMaximal benefit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply